⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ICCM News
IceCure Medical Ltd. Ordinary Shares
IceCure Medical to Attend the 2025 Maxim Growth Summit
prnewswire.com
ICCM
ICCM
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
prnewswire.com
ICCM
ICCM
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
prnewswire.com
ICCM
ICCM
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
prnewswire.com
ICCM
ICCM
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
prnewswire.com
ICCM
ICCM
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
prnewswire.com
ONCY
ANIX
ICCM
IBRX
REGN
ONCY
ANIX
ICCM
IBRX
REGN
IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications
prnewswire.com
ICCM
ICCM
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate
prnewswire.com
ICCM
ICCM